Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some
of these patients have targetable molecular alterations, and some benefit from targeted
drugs. However in many cases these drugs are not approved for the rare cancers.
In this study the aim is to do advanced molecular diagnostics to identify possible targets
for therapy, and to treat accordingly.
Phase:
Phase 2
Details
Lead Sponsor:
Oslo University Hospital
Collaborators:
Haukeland University Hospital Helse Fonna Helse Forde Helse Nord-Trøndelag HF Helse Stavanger HF Møre og Romsdal Hospital Trust Nordlandssykehuset HF Sorlandet Hospital HF StOlavs Hospital Sykehuset Innlandet HF Sykehuset Ostfold The Hospital of Vestfold University Hospital of North Norway